JP2011519867A5 - - Google Patents

Download PDF

Info

Publication number
JP2011519867A5
JP2011519867A5 JP2011507701A JP2011507701A JP2011519867A5 JP 2011519867 A5 JP2011519867 A5 JP 2011519867A5 JP 2011507701 A JP2011507701 A JP 2011507701A JP 2011507701 A JP2011507701 A JP 2011507701A JP 2011519867 A5 JP2011519867 A5 JP 2011519867A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
fatty acid
item
salt
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011507701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519867A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/042627 external-priority patent/WO2009135190A2/en
Publication of JP2011519867A publication Critical patent/JP2011519867A/ja
Publication of JP2011519867A5 publication Critical patent/JP2011519867A5/ja
Pending legal-status Critical Current

Links

JP2011507701A 2008-05-01 2009-05-01 治療用リン酸カルシウム粒子、ならびにその作製および使用方法 Pending JP2011519867A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4962708P 2008-05-01 2008-05-01
US61/049,627 2008-05-01
PCT/US2009/042627 WO2009135190A2 (en) 2008-05-01 2009-05-01 Therapeutic calcium phosphate particles and methods of making and using same

Publications (2)

Publication Number Publication Date
JP2011519867A JP2011519867A (ja) 2011-07-14
JP2011519867A5 true JP2011519867A5 (https=) 2012-06-21

Family

ID=41137579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011507701A Pending JP2011519867A (ja) 2008-05-01 2009-05-01 治療用リン酸カルシウム粒子、ならびにその作製および使用方法

Country Status (5)

Country Link
US (1) US20120128767A1 (https=)
EP (1) EP2285361A2 (https=)
JP (1) JP2011519867A (https=)
CN (1) CN102014880A (https=)
WO (1) WO2009135190A2 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010339907A1 (en) 2009-12-16 2012-07-05 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
WO2012145801A1 (en) * 2011-04-29 2012-11-01 Jagat Rakesh Kanwar Nanoparticle
WO2014064710A1 (en) 2012-10-22 2014-05-01 Department Of Biotechnology A process for the prepartion of non-viral vector for delivery of nucleic acids by mucosal route
CN103073645B (zh) * 2012-12-31 2014-06-18 浙江大学 一种生物矿化的胰岛素蛋白纳米颗粒及其制备方法和应用
GB201319548D0 (en) * 2013-11-05 2013-12-18 Medical Res Council Amorphous magnesium-substituted calcium phosphate compositions and their uses
EP3142645A4 (en) 2014-05-15 2017-12-27 Rani Therapeutics, LLC Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
WO2016078971A1 (en) * 2014-11-17 2016-05-26 Müller Werner Ernst Ludwig Georg Morphogenetically active amorphous calcium polyphosphate nanoparticles containing retinol for therapeutic applications
WO2018169954A1 (en) * 2017-03-13 2018-09-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
CA3179420A1 (en) 2020-05-20 2021-11-25 Avak Kahvejian Coronavirus antigen compositions and their uses
IL303886A (en) 2020-12-23 2023-08-01 Flagship Pioneering Inc Compositions of modified trems and uses thereof
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
ES2994006T3 (en) 2021-09-17 2025-01-16 Flagship Pioneering Innovations Vi Llc Compositions and methods for producing circular polyribonucleotides
JP2024538144A (ja) 2021-10-18 2024-10-18 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー ポリリボヌクレオチドを精製するための組成物及び方法
JP2025511756A (ja) 2022-04-08 2025-04-16 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー ワクチン及び関連する方法
US20250295687A1 (en) 2022-05-09 2025-09-25 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
US20250179492A1 (en) 2022-06-22 2025-06-05 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
AU2023372397A1 (en) 2022-10-31 2025-05-08 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
EP4615465A1 (en) 2022-11-08 2025-09-17 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing circular polyribonucleotides
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 用於將治療劑遞送至骨之組成物和方法
US20240238473A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024167885A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
IL322468A (en) 2023-02-13 2025-09-01 Flagship Pioneering Innovations Vii Llc Ionizable lipids containing degradable crosslinkers and lipid carriers for therapeutic compositions
JP2026507513A (ja) 2023-02-17 2026-03-04 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー 修飾されたウラシルを含むｄｎａ組成物
WO2024216128A1 (en) 2023-04-12 2024-10-17 Flagship Pioneering Innovations Vi, Llc Trems for use in correction of missense mutations
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
AU2024299627A1 (en) 2023-07-25 2026-01-22 Flagship Pioneering Innovations Vii, Llc Cas endonucleases and related methods
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025096807A2 (en) 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Novel therapeutic dna forms
WO2025106670A1 (en) 2023-11-14 2025-05-22 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025194019A1 (en) 2024-03-14 2025-09-18 Flagship Pioneering Innovations Vii, Llc Methods for treating liver fibrosis and non-alcoholic fatty liver disease
WO2025245188A2 (en) 2024-05-21 2025-11-27 Flagship Pioneering Innovations Vii, Llc Methods of treating liver steatosis and non-alcoholic fatty liver disease
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
CN118370728B (zh) * 2024-06-24 2024-11-08 山东则正医药技术有限公司 一种glp-1ra载药纳米颗粒和制剂及其制备方法
US20260000702A1 (en) 2024-06-26 2026-01-01 Flagship Pioneering Innovations Vii, Llc Therapeutic circular dna forms
WO2026055543A1 (en) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Modified dna compositions and related methods
WO2026055547A1 (en) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
WO2026064313A1 (en) 2024-09-17 2026-03-26 Flagship Pioneering Innovations Vii, Llc Rna compositions and related methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462751A (en) 1990-06-22 1995-10-31 The Regeants Of The University Of California Biological and pharmaceutical agents having a nanomeric biodegradable core
US5460830A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Biochemically active agents for chemical catalysis and cell receptor activation
US5460831A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US5219577A (en) 1990-06-22 1993-06-15 The Regents Of The University Of California Biologically active composition having a nanocrystalline core
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
MXPA06004698A (es) * 2003-10-27 2006-07-05 Innodia Inc Metodos y composiciones para utilizarse en el tratamiento de la diabetes.
JP5103022B2 (ja) * 2004-02-13 2012-12-19 ノッド ファーマシューティカルズ， インコーポレイテッド リン酸カルシウムナノ粒子のコア、生体分子および胆汁酸を含む粒子、ならびにそれらの製造方法および治療用途
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same

Similar Documents

Publication Publication Date Title
JP2011519867A5 (https=)
Dan et al. An update on pharmaceutical strategies for oral delivery of therapeutic peptides and proteins in adults and pediatrics
Wong et al. The role of chitosan on oral delivery of peptide-loaded nanoparticle formulation
Gedawy et al. Oral insulin delivery: existing barriers and current counter-strategies
Cai et al. Long-acting preparations of exenatide
Thwala et al. Emerging delivery platforms for mucosal administration of biopharmaceuticals: a critical update on nasal, pulmonary and oral routes
Wong Design of oral insulin delivery systems
CN1993113B (zh) 包含磷酸钙纳米颗粒核心，生物分子和胆汁酸的颗粒，其生产方法，其治疗用途
Nguyen et al. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo
Chalasani et al. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin
Peng et al. Challenges and opportunities in delivering oral peptides and proteins
US20110189299A1 (en) Pharmaceutical composition containing surface-coated microparticles
Song et al. Nanolayer encapsulation of insulin-chitosan complexes improves efficiency of oral insulin delivery
Hwang et al. Advances in oral macromolecular drug delivery
JP5491119B2 (ja) 薬物含有微粒子を含む医薬組成物およびその製造方法
EP1466610A1 (en) Medicinal compositions for nasal absorption
US20020054914A1 (en) Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
JP2013525351A (ja) ナノ粒子の医薬組成物
JP2008505919A5 (https=)
US20180271792A1 (en) Oral delivery of physiologically active substances
KR102849595B1 (ko) 안정성이 증진된 지질 기반 나노입자
Babu et al. Developments in polymeric devices for oral insulin delivery
Verma et al. Emerging trends in noninvasive insulin delivery
WO2007093999A1 (en) A gastro-retentive system for the delivery of macromolecules
Cárdenas-Bailón et al. Microencapsulation techniques to develop formulations of insulin for oral delivery: a review